{"id":358026,"date":"2023-05-17T13:05:09","date_gmt":"2023-05-17T11:05:09","guid":{"rendered":"https:\/\/medizinonline.com\/carcinome-mammaire-avec-metastases-osteoblastiques-disseminees\/"},"modified":"2023-05-23T14:46:54","modified_gmt":"2023-05-23T12:46:54","slug":"carcinome-mammaire-avec-metastases-osteoblastiques-disseminees","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/fr\/carcinome-mammaire-avec-metastases-osteoblastiques-disseminees\/","title":{"rendered":"Carcinome mammaire avec m\u00e9tastases ost\u00e9oblastiques diss\u00e9min\u00e9es"},"content":{"rendered":"\n<p><strong>Plus de 70% des personnes atteintes d&#8217;un cancer du sein sont diagnostiqu\u00e9es comme ayant des r\u00e9cepteurs hormonaux positifs et HER2 n\u00e9gatifs (HR+\/HER2-) [1]. Les donn\u00e9es des \u00e9tudes cliniques montrent qu&#8217;une combinaison de traitements avec des inhibiteurs de CDK4\/6 peut augmenter la survie sans progression (PFS, progression-free survival) et la survie globale (OS, overall survival) [2-5]. C&#8217;est le cas du cas pr\u00e9sent\u00e9, une patiente de 81 ans atteinte d&#8217;un cancer du sein HR+\/HER2 r\u00e9cidivant.<\/strong><\/p>\n\n\n\n<!--more-->\n\n\n\n<p>D\u00e9couvrez dans la vid\u00e9o tous les d\u00e9tails du cas pr\u00e9sent\u00e9 par le PD Dr. med. Marcus Vetter, Centre d&#8217;oncologie et d&#8217;h\u00e9matologie, H\u00f4pital cantonal de B\u00e2le-Campagne.<\/p>\n\n\n\n<p><\/p>\n\n\n\n<figure class=\"wp-block-embed is-provider-vimeo wp-block-embed-vimeo\"><div class=\"wp-block-embed__wrapper\">\n<iframe title=\"Vetter_FR_19.12.22\" data-src=\"https:\/\/player.vimeo.com\/video\/829411391?h=d16a50d76d&amp;dnt=1&amp;app_id=122963\" width=\"1160\" height=\"653\" frameborder=\"0\" allow=\"autoplay; fullscreen; picture-in-picture\" allowfullscreen src=\"data:image\/svg+xml;base64,PHN2ZyB3aWR0aD0iMSIgaGVpZ2h0PSIxIiB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciPjwvc3ZnPg==\" class=\"lazyload\" data-load-mode=\"1\"><\/iframe>\n<\/div><\/figure>\n\n\n\n<p>R\u00e9f\u00e9rences<\/p>\n\n\n\n<p>1. Blows, F.M., et al, <em>Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival : a collaborative analysis of data for 10,159 cases from 12 studies.<\/em> PLoS Med, 2010. <strong>7<\/strong>(5) : p. e1000279.<\/p>\n\n\n\n<p>2. Goyal, R.K., et al, <em>Overall survival associated with CDK4\/6 inhibitors in patients with HR+\/HER2- metastatic breast cancer in the United States : A SEER-Medicare population-based study.<\/em> Cancer, 2023. <strong>129<\/strong>(7) : p. 1051-1063.<\/p>\n\n\n\n<p>3. Goyal, R.K., et al, <em>Impact des inhibiteurs de CDK4\/6 sur l&#8217;utilisation de la chimioth\u00e9rapie dans les lignes de traitement pr\u00e9coces du cancer du sein HR+\/HER2- m\u00e9tastatique aux \u00c9tats-Unis.<\/em> Breast Cancer Res Treat, 2023. <strong>198<\/strong>(1) : p. 159-166.<\/p>\n\n\n\n<p>4. Li, J., et al, <em>Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer : a meta-analysis of randomized clinical trials.<\/em>Breast Cancer Res Treat, 2020. <strong>180<\/strong>(1) : p. 21-32.<\/p>\n\n\n\n<p>5. Elfgen, C. et V. Bjelic-Radisic, <em>Targeted Therapy in HR+ HER2- Metastatic Breast Cancer : Current Clinical Trials and Their Implications for CDK4\/6 Inhibitor Therapy and beyond Treatment Options.<\/em>Cancers (Basel), 2021. <strong>13<\/strong>(23).<\/p>\n\n\n\n<p>Les r\u00e9f\u00e9rences sont disponibles sur demande.<\/p>\n\n\n\n<p>Vous trouverez la derni\u00e8re information professionnelle d&#8217;Ibrance\u00ae sur le site<a> www.swissmedicinfo.ch.<\/a> <\/p>\n\n\n\n<p>PP-IBR-CHE-0423 avr 2023<\/p>\n\n\n\n<p>Contribution en ligne depuis le 17\/05\/2023<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Plus de 70% des personnes atteintes d&#8217;un cancer du sein sont diagnostiqu\u00e9es comme ayant des r\u00e9cepteurs hormonaux positifs et HER2 n\u00e9gatifs (HR+\/HER2-) [1]. Les donn\u00e9es des \u00e9tudes cliniques montrent qu&#8217;une&hellip;<\/p>\n","protected":false},"author":14,"featured_media":355332,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Cas patient  ","footnotes":""},"category":[11345,11389,11549],"tags":[],"powerkit_post_featured":[],"class_list":["post-358026","post","type-post","status-publish","format-standard","has-post-thumbnail","category-contenu-des-partenaires","category-oncologie","category-rx-fr","pmpro-has-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-05-03 03:34:43","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"fr_FR","wpml_translations":{"it_IT":{"locale":"it_IT","id":358029,"slug":"carcinoma-mammario-con-metastasi-osteoblastiche-disseminate","post_title":"Carcinoma mammario con metastasi osteoblastiche disseminate","href":"https:\/\/medizinonline.com\/it\/carcinoma-mammario-con-metastasi-osteoblastiche-disseminate\/"},"pt_PT":{"locale":"pt_PT","id":358030,"slug":"carcinoma-da-mama-com-metastases-osteoblasticas-disseminadas","post_title":"Carcinoma da mama com met\u00e1stases osteobl\u00e1sticas disseminadas","href":"https:\/\/medizinonline.com\/pt-pt\/carcinoma-da-mama-com-metastases-osteoblasticas-disseminadas\/"},"es_ES":{"locale":"es_ES","id":358028,"slug":"carcinoma-de-mama-con-metastasis-osteoblastica-diseminada","post_title":"Carcinoma de mama con met\u00e1stasis osteobl\u00e1stica diseminada","href":"https:\/\/medizinonline.com\/es\/carcinoma-de-mama-con-metastasis-osteoblastica-diseminada\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/358026","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/comments?post=358026"}],"version-history":[{"count":2,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/358026\/revisions"}],"predecessor-version":[{"id":358164,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/posts\/358026\/revisions\/358164"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media\/355332"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/media?parent=358026"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/category?post=358026"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/tags?post=358026"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/fr\/wp-json\/wp\/v2\/powerkit_post_featured?post=358026"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}